Here is more proof Yassin is a complete moron. (185 scripts not patients and 12 a week is the total)
The biotech company has since seen 185 global prescriptions written for the medication, which places the company well on track to reach its goal of 250-300 patients by the end of the year, as reported by The Street. In an earnings call at the end of April, CEO Marc Beer noted that the number of Juxtapid prescriptions issued each week has been steadily increasing since the launch and, as of April 30, was at 12 a week. Furthermore, Juxtapid's steep pricing - one year of therapy costs $250,00 - is expected to help Aegerion generate $15 - $25 million in revenue this year.
Uh, and you think that 185 prescriptions were for fewer patients?
You think they are just buying extra because it is so cheap at $300,000 per patient per year.
So, let's get to the difference. They had cited 75 patients under care, and were rapidly increasing, as they had 185 prescriptions written (but not yet filled - they were just filling them, but had not realized that revenue at the time of the CC). So it isn't really all that hard to understand.
Thank you for making my point though and backing me up. I claimed 185 and so did you. I claimed 50/month and at 12/week = 12*4weeks = 48 but there is a little more than 4 weeks in a month, so 50.
Bingo. Thank you for your assistance and your cooperation.
What I think people are getting confused with is that the company hyped that they had 185 scripts but in reality, 110 of those scripts ended up going worthless as only 75 of those turned into actual customers in 2013. Then they gave this figure of 300 customers in 2013 but this again is probably the script number of 300 which at the actual conversion ratio of 40% into actual customers predicts an eventual customer base of 120 by the end of 2012.